Genetically modified animal

Non-GMO Project: Genetically engineered fish and meat coming to your table... soon?

Retrieved on: 
Wednesday, May 5, 2021
Articles, Life sciences, Biology, Genetic engineering, Biotechnology, Molecular biology, Biological engineering, Emerging technologies, Genetically modified animal, Food and Drug Administration, Food

This extension offers a rare opportunity for the public to influence the new administration to withdraw the dangerous proposal.

Key Points: 
  • This extension offers a rare opportunity for the public to influence the new administration to withdraw the dangerous proposal.
  • Furthermore, the Project says, "We all have a fundamental right to at least know what is in our food.
  • "\nThe risks are real, despite the biotechnology industry\'s lobbying effort to deregulate, and its claims that these technologies are safe.
  • It also speaks to the need for a stringent FDA review process for genetically engineered animals so that the meat and/or milk of these animals doesn\'t eventually slip into the food supply chain.

EFSA advises on risk assessment of engineered gene drives

Retrieved on: 
Thursday, November 12, 2020
Genetic engineering, Molecular biology, Articles, Branches of biology, Life sciences, Genetically modified organisms, Emerging technologies, Gene drive, Sterilization, Genetically modified animal, European Food Safety Authority, Hazards of synthetic biology

EFSAs existing guidelines for the risk assessment of genetically modified animals are adequate for evaluating risks associated with gene drive modified insects.

Key Points: 
  • EFSAs existing guidelines for the risk assessment of genetically modified animals are adequate for evaluating risks associated with gene drive modified insects.
  • However, further guidance is needed for some areas, such as molecular characterisation, environmental risk assessment and post-market environmental monitoring, say EFSAs experts on Genetically Modified Organisms.
  • There are already proposals to use engineered gene drives to suppress or modify mosquito populations, control agricultural pests, eradicate invasive species, and rescue endangered species.
  • The European Commission asked EFSA to assess whether its existing guidelines for the risk assessment of genetically modified animals can be used for the risk assessment of gene drive modified insects.

Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals

Retrieved on: 
Tuesday, November 5, 2019
Medical specialties, Branches of biology, Immunology, Medicine, Genetic engineering, Glycoproteins, Immune system, Biotechnology, Antibody, Genetically modified animal, Transgene, Polyclonal antibodies

This license enables Talem to access Ligand's unique OmniAb platform for use with Talem's leading antibody discovery capabilities.

Key Points: 
  • This license enables Talem to access Ligand's unique OmniAb platform for use with Talem's leading antibody discovery capabilities.
  • OmniAb is a genetically engineered platform for the generation of diverse mono- and bispecific, fully human antibodies, and the industry's only platform comprised of the three species rats, mice, and chickens.
  • OmniAb is a three-species transgenic-animal platform consisting of five different technologies used for producing mono- and bispecific human therapeutic antibodies.
  • OmniAb is a patent-protected transgenic animal platform used in the discovery of fully human mono-and bispecific therapeutic antibodies.